相关实验视频

Updated: Jan 11, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

贝卢莫苏迪尔治疗慢性移植对宿主疾病:系统性审查和元分析

Kristin Rathje¹, Nico Gagelmann¹, Silke Heidenreich¹

¹Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Transplantation and cellular therapy

|November 15, 2025

概括

贝卢莫苏迪尔在干细胞移植后对慢性移植对宿主疾病 (cGvHD) 显示出良好的结果. 这种向治疗是有效和安全的,在早期治疗阶段需要进一步研究.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

慢性移植与宿主疾病 (cGvHD) 是全源造血干细胞移植后的一种严重并发症.
它通常对标准治疗具有抗性,需要新的治疗方法.
贝卢莫苏迪尔是一种ROCK2抑制剂,具有免疫调节和抗纤维性益处,已被批准用于第三线治疗.

研究的目的:

系统地审查和分析 belumosudil 在成年cGvHD患者的疗效和安全性.
评估整体反应率 (ORR),器官特异性反应,生存结果和不良事件.
探索影响治疗反应的因素,包括先前的鲁克索利提尼布暴露和疾病特征.

主要方法:

16项研究的系统综述和元分析,包括651名成人cGvHD患者.
包括前性和后性研究,报告临床结果和安全性.
贝叶斯随机效应模型和元回归的应用,用于聚合结果估计和异质性评估.

主要成果:

聚合的整体响应率 (ORR) 为60%,前性研究的比率更高 (73%).
在胃肠道 (52%) 和关节/筋膜 (52%) 的参与中观察到有利的器官反应;肺部cGvHD显示出不良反应 (25%).
之前的鲁克索利提尼布暴露与较低的ORR相关. 总生存率为87%,无故障生存率为57%. 不良事件是可以管理的,严重的药物相关事件在≤13%.

结论:

贝卢莫苏迪尔在耐火性cGvHD患者中显示出显著的疗效和可管理的安全性.
这些发现支持 belumosudil 作为cGvHD 的一个有价值的治疗选择.
建议进行进一步的研究,以评估 belumosudil 在疾病和治疗过程的早期阶段.

关键词:

在GVHD中,GVHD是指GVHD 目前还没有osudil.瑞克索利提尼布 (Ruxolitinib) 是一种药物.移植移植移植移植

更多相关视频

Murine Full-thickness Skin Transplantation

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...